Waikato District Health Board (DHB) has come under fire in a report from the Office of the Auditor-General after a 21-month inquiry into its SmartHealth virtual care system failure.
Health Minister David Clark has announced the government is putting right a decade’s worth of underpayment to nurses, doctors and other health workers relating to the Holidays Act, with $550-650 million owed to staff.
UK ophthalmologists delivered the world’s first tele-examination of an eye using 5G broadband, which was streamed live between London and a conference in Edinburgh.
Specialty sports eyewear came under the spotlight during Rugby World Cup 2019 when All Black Ardie Savea wore specially-approved googles during a pool play game in Japan. The popular loose forward was acting on doctor’s advice by wearing the mask to protect his deteriorating eye sight for New Zealan
The Australian KeepSight screening initiative was launched at the end of 2018 and started in earnest at the beginning of this year.
The 2019 Doug Perkins Medals for Clinical Excellence were awarded to Specsavers Dunedin and Specsavers Dubbo.
The first World Report on Vision was launched on World Sight Day on 10 October by the World Health Organisation (WHO) and its eye health partners - International Agency for the Prevention of Blindness (IAPB), Sightsavers and The Fred Hollows Foundation - to address unequal access to eye care globall
Optometry Australia is urging therapeutically endorsed optometrists prescribing eye-drops for myopia to clearly label the script ‘Must be compounded’ following incidents of Australian children receiving the wrong eye-drops from pharmacists.
US research has identified high levels of retinol-binding protein 3 (RBP3) can protect against, and potentially treat, diabetic eye disease.
RANZCO has set up The Future of Ophthalmology Taskforce, an independent advisory committee to look at how artificial intelligence (AI) will shape the future of ophthalmology.
A Taiwanese study showed diabetics with severe sleep apnoea are at higher risk of treatment-resistant diabetic macular oedema.
Phase 1 clinical trial data shows promising results for patients with wet age-related macular degeneration (AMD), maintaining vision for at least six months after a single intravitreal injection of gene therapy.
